Brazilian Maker of Sputnik V Vaccine Foresees Approval of Tests by Next Week

As soon as Brazil’s health regulator approves the trials, the company will start and will take 60-90 days.

RIO DE JANEIRO, BRAZIL - The Brazilian pharmaceutical company that will make Russia’s Sputnik V vaccine against COVID-19 expects regulatory approval for Phase III tests by this week or early next week at the latest, Chief Executive Officer Fernando Marques said on Tuesday, February 2nd.

Marques said the strong efficacy results from late stage trials in Russia, published on Tuesday by The Lancet - 91.6% effective against symptomatic COVID-19 - will help speed up approval in Brazil sought by his firm Subscribe to our Premium Membership Plan. Already Subscribed?